Lumitin Conbercept Ophthalmic Injection

1. Indications and Usage
Conbercept is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and myopic choroidal neovascularization (mCNV).
2. Dosage and Administration
Recommended Dosage: The recommended dose is 2.5 mg administered via intravitreal injection.
Administration Schedule: For nAMD, the initial regimen typically consists of monthly injections for three doses, followed by an individualized treatment and monitoring schedule based on disease activity.
Procedure: The injection must be performed by a qualified ophthalmologist using strict aseptic techniques to minimize the risk of endophthalmitis.
3. Mechanism of Action
Conbercept is a recombinant fusion protein that acts as a vascular endothelial growth factor (VEGF) trap. It binds to and inhibits VEGF-A, VEGF-B, and PlGF, thereby blocking the signaling pathways responsible for choroidal neovascularization and vascular permeability.
4. Safety and Warnings
Ocular Infections: Serious ocular infections, including endophthalmitis and retinal detachment, may occur following intravitreal injection.
Intraocular Pressure: An increase in intraocular pressure has been observed post-injection.
Retinal Detachment: Risk of retinal tear or detachment exists, particularly in patients with high myopia.
Systemic Arterial Thromboembolic Events: Caution is advised in patients with a history of arterial thromboembolic events.
5. Adverse Reactions and Clinical Research
Adverse Reactions: The most common adverse reactions include conjunctival hemorrhage, vitreous floaters, increased intraocular pressure, eye pain, and cataract.
Clinical Research: In pivotal clinical trials (e.g., CIRRUS, VISTA, VISION), conbercept demonstrated significant improvement in visual acuity and reduction in central foveal thickness compared to sham treatment.
6. Drug Interactions
No formal drug interaction studies have been conducted for intravitreal injections. Systemic interactions are not anticipated due to the localized nature of administration and limited systemic absorption.
7. Pharmaceutical Information
Composition: Active ingredient is conbercept. Excipients include sodium chloride, monobasic sodium phosphate, dibasic sodium phosphate, and water for injection.
Appearance: Clear, colorless to slightly opalescent liquid.
Storage: Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze or shake.